Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a securities fraud class action lawsuit due to alleged failures in disclosing critical information regarding its manufacturing processes and regulatory submissions related to the INO-3107 product [1]. Group 1: Lawsuit Details - The lawsuit claims that from October 10, 2023, to December 26, 2025, Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device [1]. - It is alleged that Inovio is unlikely to submit the Biologics License Application (BLA) for INO-3107 to the FDA by the second half of 2024 [1]. - The company reportedly lacked sufficient information to support the eligibility of INO-3107 for FDA accelerated approval or priority review [1]. Group 2: Impact on Company Statements - The lawsuit asserts that the overall regulatory and commercial prospects of INO-3107 were overstated by the company [1]. - Positive statements made by Inovio regarding its business, operations, and future prospects were claimed to be materially misleading and lacked a reasonable basis [1].